Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion

Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog

(2011) Xinyue Chen et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Benefits and risks of interferon therapy for hepatitis B

(2010) Robert Perrillo   HEPATOLOGY

Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a

(2009) Patrick Marcellin et al.   GASTROENTEROLOGY

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study

(2009) Rami Moucari et al.   JOURNAL OF HEPATOLOGY

Hepatitis B and hepatitis C in 2009

(2009) Patrick Marcellin   LIVER INTERNATIONAL

HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma

(2008) Man–Fung Yuen et al.   GASTROENTEROLOGY

Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b

(2008) Erik H.C.J. Buster et al.   GASTROENTEROLOGY

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

(2008)   JOURNAL OF HEPATOLOGY

Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

(2008) Patrick Marcellin et al.   NEW ENGLAND JOURNAL OF MEDICINE